NCT06998095View on ClinicalTrials.gov

Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

Not yet recruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Severe Asthma

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY